tbuckley/cabot-search huggingface dataset:
Abstract 12205: Prediction of Heart Failure Symptoms Using Framingham and ARIC Scores in Patients With Non Ischemic Risk Factors at 1 Year Follow up
Authors: Hong Yang, Kazuaki Negishi, Mark Nolan, Ying Wang, Faisal Khan, Thomas Marwick
Journal: Circulation (2015)

Background: The Framingham heart failure score (FHS) and ARIC heart failure (HF) risk calculator are risk prediction tools that might facilitate the targeting of prevention strategies in pts with HF risk factors. We sought to compare their performance of predicting new HF symptoms in pts with risk factors. Method: Subjects ≥65 yo, with ≥ 1 HF risk (hypertension, type 2 diabetes, obesity, previous chemotherapy, family history of HF or previous cardiac history) were recruited from the local community. Absolute risk of incident HF risk was calculated using ARIC and FHS risk scores at baseline. Subjects underwent standard questionnaire, electrocardiogram, comprehensive echocardiogram and 6-minute walk (6MW) test. New HF based on Framingham criteria were assessed after a follow-up of 14±4 months. Results: Among 308 subjects (age 71±5 y; 50% men), median (IQR) 4 year risk of FHS and ARIC score were 4.0 (2-6.5) % and 6.2 (3.6-11.4) %, respectively. 19 participants developed new HF signs and symptoms (Framingham criteria). Compared with those remaining asymptomatic, those with new HF had higher ARIC score (p&lt;0.001), more impaired GLS (p=0.036), larger left atrium volume (p=0.05) and left ventricular (LV) mass (p=0.049. They also had significant baseline 6MW test distance (p=0.003). There was no difference between their FHS score (p=0.325) and other conventional diastolic measures including LV ejection fraction, mitral E/A, e’ and E/e’ (p=0.108-0.804). AUC of ARIC and FHS were 0.74 (p=0.001) and 0.63 (p=0.057), respectively. The AUC of 6MW was 0.698 (p=0.005) (figure). Conclusion: The ARIC score appears to be more predictive than FHS score in prediction of new HF symptoms in non-ischemic stage A HF. 6MW test maybe used as an effective screening tool in community based process.
P018 Afatinib Named Patient Use Program in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
Authors: G. Chang, D.C. Lam, C. Tsai, Y. Chen, J. Shih, S. Aggarwal, S. Wang, S. Kim, Y. Kim, I. Wahid, R. Li, W. Lim, V. Sriuranpong, T.T. Chan, J.C. Yang, C. Yu, W. Liao, C. Ho, R.M. Lorence, P. Carriere, C. Raabe, A. Cseh, K. Park
Journal: Journal of Thoracic Oncology (2018)
Abstract 20665: Alterations in Coronary Microvascular NO Signaling in Exercising Swine With Multiple Comorbidities
Authors: Oana Sorop, Jens Van De Wouw, Ruben W van Drie, Jaap A Joles, Daphne Merkus, Dirk J Duncker
Journal: Circulation (2017)

Introduction: Diabetes mellitus (DM), hypercholesterolemia and chronic kidney disease (CKD) cause alterations in coronary microvascular NO-production and/or signaling, leading to impaired myocardia...
A Phase I Trial Evaluating Aerosol Administration Of A Candidate Tb Vaccine, Mva85a, As A Way To Induce Potent Local Cellular Immune Responses And Avoid Anti-Vector Immunity
Authors: Thomas Z-Rm., I Satti, M Wilkie, S Harris, M Riste, A Hamidi, A Minhinnick, H Bettinson, H McShane
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications
Authors: Katherine J. Kearney, Nikoletta Pechlivani, Rhodri King, Christian Tiede, Fladia Phoenix, Ramsah Cheah, Fraser L. Macrae, Katie J. Simmons, Iain W. Manfield, Kerrie A. Smith, Benjamin E. J. Spurgeon, Khalid M. Naseem, Robert A. S. Ariens, Michael J. McPherson, Darren C. Tomlinson, Ramzi A. Ajjan
Journal: Blood (2018)
Use of a Mouse Model of Experimentally Induced Endometriosis to Evaluate and Compare the Effects of Bisphenol A and Bisphenol AF Exposure
Authors: Rebecca L. Jones, Stephanie A. Lang, Jessica A. Kendziorski, Alexis D. Greene, Katherine A. Burns
Journal: Environmental Health Perspectives (2018)

Endometriosis is a gynecological disease affecting 1 in 10 women of reproductive age. Endometriosis incidence has risen; however, whether this rise is due to disease awareness or environmental contamination is not known.
Severe Hemochromatosis Arthropathy in the Absence of Iron Overload
Authors: Samer Chehade, Paul C. Adams
Journal: Hepatology (2018)

1Department of MedicineUniversity HospitalLondonONCanada * Address Correspondence and Reprint Requests to: Paul C. Adams, M.D. Department of Medicine, University Hospital 339 Windermere Road London, ON, Canada N6A 5A5 E‐mail: [email protected] Tel.: +1‐519‐685‐8500, ext. 35375
Abstract P169: Antibodies to Citrullinated Protein Antigens (ACPA), Left Ventricular Mass and Ejection Fraction in the Multi-Ethnic Study of Atherosclerosis
Authors: Jan M Hughes-Austin, Ronit Katz, Darcy S Majka, Michael H Criqui, William H Robinson, Gary S Firestein, W G Hundley, Joachim H Ix
Journal: Circulation (2018)

Background: Antibodies to citrullinated proteins (ACPA) are elevated in patients with rheumatoid arthritis (RA) and have been linked to altered left ventricular (LV) structure and function in RA. ACPA are detectable years before RA onset and in some individuals who do not develop RA. Among individuals without RA and without heart failure in MESA, we investigated associations between ACPA, LV mass, and LV ejection fraction (LVEF). Methods: In a cross-sectional subsample of 1232 MESA participants, we measured ACPA using a multiplex array of 38 different ACPA. Each ACPA was defined as positive (+) if &gt; 95 th percentile cut-off in MESA. Number of (+) ACPA were summed for each participant (range 0-38). We compared ACPA(-) to ACPA(+) participants, and examined the association of number of ACPA with both outcomes. LVmass (g) and LVEF (%) were measured on cardiac MRI. We analyzed associations using generalized linear regression and adjusted for covariates listed in the table. Results: Mean age was 65 years. The sample was 50% women, 40% Caucasian; and 31% had ≥ 1 (+) ACPA. Among ACPA(+) participants, median number (+) was 2 (IQR 1-6). ACPA(+) participants were similar to ACPA(-) participants in age, gender, and race/ethnicity, but had higher IL-6 levels. Mean LVmass for ACPA(+) vs ACPA(-) participants was 147g(39) and 146g(39), respectively; mean LVEF was 69%(7) and 70%(8), respectively. In adjusted analysis, LVmass and LVEF did not differ significantly between ACPA(+) and ACPA(-) participants. However, for every higher number of (+) ACPA, LVEF was 0.07% lower (p=0.02). Among individual ACPA, antibodies to Filaggrin 48-65 arg2v1cyc (p=0.04), histone 2B (p=0.01), and histone 2Bcit (p=0.02) were significantly associated with lower LVEF. No individual ACPA was associated with LVmass. Conclusion: In community-dwelling individuals without RA or heart failure, greater numbers of detectable ACPA were associated with lower LVEF, but not LVmass. Future studies are required to determine whether ACPA are associated with incident heart failure.
Abstract 17129: Altered Subendocardial Perfusion Reserve in Patients with Normal-High Blood Pressure Assessed by Quantitative Analysis of Myocardial Perfusion MRI
Authors: Hiroshi Nakajima, Hajime Sakuma, Katsuya Onishi, Shiro Nakamori, Motonori Nagata, Masaki Ishida, Kakuya Kitagawa, Kaoru Dohi, Mashio Nakamura, Masaaki Ito
Journal: Circulation (2011)

Background Myocardial perfusion reserve (MPR) reflects endothelial function of the coronary artery and can be altered by various atherosclerotic risk factors. We previously reported that hypertension is associated with impairment of MPR, especially subendocardial MPR. However, information is limited regarding the impact of normal-high blood pressure (systolic blood pressure (SBP) of 130-139mmHg, diastolic blood pressure (DBP) of 85-89mmHg, or both) on MPR. Purpose To determine if MPR was already altered in patients with normal-high blood pressure by using a quantitative analysis of stress-rest myocardial perfusion MRI. Method We studied 73 subjects without hypertension (SBP&lt;140mmHg and DBP&lt;90mmHg) who did not exhibit regional myocardial ischemia and myocardial scar on stress CMR study. Subjects were divided into two groups (Normal-high group: n=19, 68±9 year-old, 17 men; Normal-optimal group (SBP&lt;130mmHg and DBP&lt;85mmHg): n=54, 68±10 year-old, 33 men) according to blood pressure. Stress-rest myocardial perfusion MRI was acquired with blood signal saturation correction, and absolute subendocardial and epicardial myocardial blood flow (MBF) and MPR were quantified. MPR were calculated as stress MBF divided by rest MBF. Result The averaged transmural MPR in subjects with normal-high blood pressure was significantly lower than that in normal-optimal group.(2.74±1.61 vs. 3.80±2.03, p=0.043). When subepicardial MBF and subendocardial MBF were analyzed separately, MPR in subepicardial myocardium did not demonstrate significant difference between two groups (3.09±1.66 vs. 4.29±2.49, p=ns). In contrast, MPR in subendocardial myocardium was significantly reduced in the high-normal group than in the normal-optimal group. (2.57±1.51 vs. 3.65±1.66, p=0.015) Conclusion In the current study evaluating subjects without regional myocardial ischemia or significant coronary artery disease, subendocardial MPR was significantly decreased in the group with normal-high blood pressure. The result of this study suggests that endothelial function of the coronary artery is already altered in patients with normal-high blood pressure.
Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)
Authors: Amy Wang, Howard Weiner, Richard A. Larson, Olatoyosi Odenike, Andrew S Artz, Michael R. Bishop, Lucy Godley, Michael Thirman, Satyajit Kosuri, Jane Churpek, Emily K Curran, Kristen Pettit, Wendy Stock, Hongtao Liu
Journal: Blood (2018)
Abstract 17225: Therapeutic Strategies Following Major Bleeding in Atrial Fibrillation: Findings From ORBIT-AF
Authors: Emily C O'Brien, DaJuanicia N Simon, Gregg C Fonarow, Jack E Ansell, Peter R Kowey, Bernard J Gersh, Kenneth Mahaffey, Eric D Peterson, Jonathan P Piccini, Elaine M Hylek
Journal: Circulation (2015)

Background: Little information exists on clinical characteristics and treatment patterns of patients with atrial fibrillation (AF) following a major bleeding event in clinical practice. Methods: We used data from a large, national outpatient registry, ORBIT-AF (2010 – 2011), to evaluate event characteristics and oral anticoagulation (OAC) management following a major bleeding event. Major bleeds were defined according to ISTH criteria. We compared baseline characteristics among patients who persisted on OAC therapy at the first clinic visit following a major bleed and those in whom OAC was discontinued using chi-squared tests. Results: Of 10135 patients enrolled in ORBIT-AF, n=791 (7.8%) bleeding events occurred during 2 years of follow-up. Among patients who were receiving OA, n=632 (3.5 per 100 person years) experienced a major bleed. Of these, 67.3% experienced a fall in hemoglobin and 46.8% required transfusion of 2 of more units of red blood cells. Critical site bleeding occurred in 150 OAC patients, with the majority of these classified as intracranial bleeding (n= 89), followed by retroperitoneal (n=25) and intraocular (n=17). Fatal bleeds occurred in 37 patients (5.9% of all major bleeds). Nearly one-third of patients (31.0%) discontinued OAC therapy following the major bleeding event. Compared with those who persisted on OAC, patients who discontinued OAC were more likely to have hypertension and CKD. Those who discontinued OAC were more likely to have gastrointestinal or CNS site bleeding compared with those who persisted (Table). Conclusions: One in three patients who experienced a major bleed were no longer optimally anticoagulated after the event. Those who discontinued OAC had a greater comorbidity burden and more likely to have bleeding in a critical site those who persisted on OAC.
Actelion Pharmaceuticals pays $360m to settle US government claims of kickbacks to patients
Authors: Owen Dyer
Journal: BMJ (2018)

Actelion Pharmaceuticals, which was acquired by Johnson and Johnson last year, will pay $360m (£285m; €315m) to settle US government allegations that it funnelled money to Medicare patients, illegally helping them to cover the co-payment for its pulmonary artery hypertension drug Tracleer (bosentan).

The settlement is the latest and biggest in a federal probe into patient charities associated with drug companies, and their role in stimulating demand from patients whose drug expenses are subsidised by government.

Medicare, the national programme that insures many health costs for Americans aged over 65, covers most of the cost of prescription drugs but requires that a proportion be paid by the individual.

The co-payment is meant to discourage high drug prices by making …
Controversies About Lyme Disease—Reply
Authors: Eugene D. Shapiro, Gary P. Wormser
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Elevated Heme Synthesis and Uptake Underpin Intensified Oxidative Metabolism and Tumorigenic Functions in Non–Small Cell Lung Cancer Cells
Authors: Sagar Sohoni, Poorva Ghosh, Tianyuan Wang, Sarada Preeta Kalainayakan, Chantal Vidal, Sanchareeka Dey, Purna Chaitanya Konduri, Li Zhang
Journal: Cancer Research (2019)

Abstract Tumors of human non–small cell lung cancer (NSCLC) are heterogeneous but exhibit elevated glycolysis and glucose oxidation relative to benign lung tissues. Heme is a central molecule for oxidative metabolism and ATP generation via mitochondrial oxidative phosphorylation (OXPHOS). Here, we showed that levels of heme synthesis and uptake, mitochondrial heme, oxygen-utilizing hemoproteins, oxygen consumption, ATP generation, and key mitochondrial biogenesis regulators were enhanced in NSCLC cells relative to nontumorigenic cells. Likewise, proteins and enzymes relating to heme and mitochondrial functions were upregulated in human NSCLC tissues relative to normal tissues. Engineered heme-sequestering peptides (HSP) reduced heme uptake, intracellular heme levels, and tumorigenic functions of NSCLC cells. Addition of heme largely reversed the effect of HSPs on tumorigenic functions. Furthermore, HSP2 significantly suppressed the growth of human NSCLC xenograft tumors in mice. HSP2-treated tumors exhibited reduced oxygen consumption rates (OCR) and ATP levels. To further verify the importance of heme in promoting tumorigenicity, we generated NSCLC cell lines with increased heme synthesis or uptake by overexpressing either the rate-limiting heme synthesis enzyme ALAS1 or uptake protein SLC48A1, respectively. These cells exhibited enhanced migration and invasion and accelerated tumor growth in mice. Notably, tumors formed by cells with increased heme synthesis or uptake also displayed elevated OCRs and ATP levels. These data show that elevated heme flux and function underlie enhanced OXPHOS and tumorigenicity of NSCLC cells. Targeting heme flux and function offers a potential strategy for developing therapies for lung cancer. Significance: These findings show that elevated heme availability due to increased heme synthesis and uptake causes intensified oxygen consumption and ATP generation, promoting tumorigenic functions and tumor growth in NSCLC.
Junior doctors could be stopped from working in UK under new immigration rules, health leaders warn
Authors: Gareth Iacobucci
Journal: BMJ (2018)

Junior doctors and other healthcare staff from the European Union could be blocked from taking up valuable posts in the NHS under new UK immigration rules, healthcare leaders have warned.

The warning came as the government published its long delayed immigration white paper setting out proposed new rules for migrants from the EU after Brexit.

The white paper,1 published on Wednesday 19 December, will end free movement, offer no preferential treatment to EU citizens over migrants from outside the EU, and prioritise more highly skilled workers. Ministers intend to establish a new, single immigration system for skilled migrants from outside and inside the EU from 2021.

The government has accepted a recommendation from the Migration Advisory Committee to scrap the current annual cap on the number of “tier 2” visas issued …
Abstract 19430: Combination of Two Different Microchips in Total Thrombus-Formation Analysis System Predicts High Risk Patients With Periprocedural Bleeding Events Events After Percutaneous Coronary Intervention
Authors: Yu Oimatsu, Koichi Kaikita, Masanobu Ishii, Tatsuro Mitsuse, Miwa Ito, Yuichiro Arima, Daisue Sueta, Hisanori Kanazawa, Seiji Takashio, Eiichiro Yamamoto, Kenji Sakamoto, Yasuhiro Izumiya, Sunao Kojima, Kenichi Tsujita
Journal: Circulation (2017)

Periprocedural bleeding event is one of the most common complications after percutaneous coronary intervention (PCI). The Total Thrombus-formation Analysis System (T-TAS) was developed as a system ...
Migraine-Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK
Authors: Perrine Royal, Alba Andres-Bilbe, Pablo Ávalos Prado, Clément Verkest, Brigitte Wdziekonski, Sébastien Schaub, Anne Baron, Florian Lesage, Xavier Gasull, Joshua Levitz, Guillaume Sandoz
Journal: Neuron (2018)
Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings
Authors: Jeffrey K. Lee, Christopher D. Jensen, Theodore R. Levin, Ann G. Zauber, Joanne E. Schottinger, Virginia P. Quinn, Natalia Udaltsova, Wei K. Zhao, Bruce H. Fireman, Charles P. Quesenberry, Chyke A. Doubeni, Douglas A. Corley
Journal: JAMA Internal Medicine (2018)

<h3>Importance</h3> Guidelines recommend a 10-year rescreening interval after a colonoscopy with normal findings (negative colonoscopy results), but evidence supporting this recommendation is limited. <h3>Objective</h3> To examine the long-term risks of colorectal cancer and colorectal cancer deaths after a negative colonoscopy result, in comparison with individuals unscreened, in a large, community-based setting. <h3>Design, Setting, and Participants</h3> A retrospective cohort study was conducted in an integrated health care delivery organization serving more than 4 million members across Northern California. A total of 1 251 318 average-risk screening-eligible patients (age 50-75 years) between January 1, 1998, and December 31, 2015, were included. The study was concluded on December 31, 2016. <h3>Exposures</h3> Screening was examined as a time-varying exposure; all participants contributed person-time unscreened until they were either screened or censored. If the screening received was a negative colonoscopy result, the participants contributed person-time in the negative colonoscopy results group until they were censored. <h3>Main Outcomes and Measures</h3> Using Cox proportional hazards regression models, the hazard ratios (HRs) for colorectal cancer and related deaths were calculated according to time since negative colonoscopy result (or since cohort entry for those unscreened). Hazard ratios were adjusted for age, sex, race/ethnicity, Charlson comorbidity score, and body mass index. <h3>Results</h3> Of the 1 251 318 patients, 613 692 were men (49.0%); mean age was 55.6 (7.0) years. Compared with the unscreened participants, those with a negative colonoscopy result had a reduced risk of colorectal cancer and related deaths throughout the more than 12-year follow-up period, and although reductions in risk were attenuated with increasing years of follow-up, there was a 46% lower risk of colorectal cancer (hazard ratio, 0.54; 95% CI, 0.31-0.94) and 88% lower risk of related deaths (hazard ratio, 0.12; 95% CI, 0.02-0.82) at the current guideline-recommended 10-year rescreening interval. <h3>Conclusions and Relevance</h3> A negative colonoscopy result in average-risk patients was associated with a lower risk of colorectal cancer and related deaths for more than 12 years after examination, compared with unscreened patients. Our study findings may be able to inform guidelines for rescreening after a negative colonoscopy result and future studies to evaluate the costs and benefits of earlier vs later rescreening intervals.
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes
Authors: Mohammad Abufaraj, Beat Foerster, Eva Schernhammer, Marco Moschini, Shoji Kimura, Melanie R. Hassler, Mark A. Preston, Pierre I. Karakiewicz, Mesut Remzi, Shahrokh F. Shariat
Journal: European Urology (2018)
A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation
Authors: Jae H. Park, Maria Lia Palomba, Connie Lee Batlevi, Isabelle Riviere, Xiuyan Wang, Brigitte Senechal, Richard R. Furman, Yvette Bernal, Malloury Hall, John Pineda, Claudia Diamonte, Elizabeth Halton, Renier J. Brentjens, Michel Sadelain
Journal: Blood (2018)
Incidental Detection of Plasma Cell Neoplasm on 18F-Choline PET/CT Imaging
Authors: Jiwan Paudel, Navneet Singla, Anish Bhattacharya, Rajender Kumar Basher, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2018)

F-Fluorocholine is a relatively new, extremely versatile radiotracer for detecting proliferative or mitogenic activity. Its diagnostic potential has been explored in cancers of the prostate, liver, esophagus, breast, brain, and lung, as well as lymphoma, sarcoma, melanoma, and parathyroid adenomas. The authors present a case where fluorocholine PET/CT performed for characterizing a space-occupying lesion in the brain revealed intensely tracer-avid skull lesions with intracranial soft tissue component and multiple other skeletal lesions. Fine-needle aspiration cytology from the skull and chest wall lesions confirmed the diagnosis of plasma cell neoplasm.
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Primary Myelofibrosis Among Stem Cell Source Groups
Authors: Makoto Murata, Katsuto Takenaka, Naoyuki Uchida, Yukiyasu Ozawa, Kazuteru Ohashi, Sung-Won Kim, Kazuhiro Ikegame, Yoshiko Atsuta, Makoto Hirokawa, Takahiro Fukuda, Takeshi Kondo
Journal: Blood (2018)
Abstract 15828: Pro-Atrial Natriuretic Peptide (proANP) as a Stable Circulating ANP Form That is Not Affected by Neprilysin-Mediated Cleavage
Authors: Alexander G Semenov, Evgeniya F Feygina, Natalia N Tamm, Daria V Serebryanaya, Alexey G Katrukha
Journal: Circulation (2017)

Background: A novel heart failure drug, EntrestoTM (LCZ696), which combines a neutral endopeptidase (neprilysin) inhibitor and an inhibitor of the angiotensin II receptor, was suggested to augment ...